טוען...
Somatic mutation of the cohesin complex subunit confers therapeutic vulnerabilities in cancer
A synthetic lethality–based strategy has been developed to identify therapeutic targets in cancer harboring tumor-suppressor gene mutations, as exemplified by the effectiveness of poly ADP-ribose polymerase (PARP) inhibitors in BRCA1/2-mutated tumors. However, many synthetic lethal interactors are l...
שמור ב:
| הוצא לאור ב: | J Clin Invest |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
American Society for Clinical Investigation
2018
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6025969/ https://ncbi.nlm.nih.gov/pubmed/29649003 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/JCI98727 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|